ArticleThe oncologist2026
Primary brainstem lymphoma: clinical characteristics, treatment methods, and prognostic factors of 56 patients.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPrimary brainstem lymphoma (PBSL) is rare and generally has a poor prognosis. This study aimed to analyze the clinical, therapeutic, and prognostic factors in a single-center retrospective cohort.
methodsFifty-six patients diagnosed with PBSL from January 2018 to December 2022 were retrospectively enrolled. Data on the clinical course of disease, pathological parameters, neuroradiological imaging, laboratory results, and survival data were collected and analyzed.
resultsThe median age at diagnosis was 56 years (range: 10-77), and 23 (41.1%) patients had a Karnofsky Performance Score ≤60. The mid-brain was the most commonly involved brainstem region (35.7%). The histological type of all patients was diffuse large B-cell lymphoma. The first-line treatment was high-dose methotrexate (HD-MTX)-based chemotherapy, with an overall response rate (ORR) of 70.5%, of which 62.1% achieved complete response. For relapsed or refractory disease, radiotherapy was the most common salvage therapy and significantly improved overall survival (OS). With a median follow-up of 56 months, the median OS for the entire cohort was 30 months (95% CI 18-42 months). In both univariate and multivariate analysis, an age of ≥60 years at diagnosis was a significant prognostic factor for poor OS (hazard ratio [HR] 3.086, P = .003, 95% CI 1.467-6.492) and progression-free survival (HR 2.309, P = .030, 95% CI 1.087-4.905).
conclusionsPBSL has worse survival outcomes compared to tumors in other sites. HD-MTX chemotherapy remains effective, achieving a high ORR. Radiotherapy is an important salvage alternative for rapidly reducing brainstem lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.